Observational studyJournal of the American Heart Association2025
Effects of Warfarin on the Risks of Mortality, Acute Heart Failure, and Infection Resolution in Patients With Infective Endocarditis: A Target Trial Emulation.
Observational study in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfective endocarditis (IE) can be complicated by acute heart failure and bacteremia, which can account for increased mortality. The role of anticoagulation with warfarin in IE is controversial. This study aimed to study the effects of anticoagulation with warfarin on survival in patients with IE, through reducing the risks of thromboembolism and possibly shortening infection time.
methodsThis was a retrospective population-based cohort study using the Clinical Data Analysis and Reporting System from Hong Kong. Patients diagnosed with IE between January 1, 1997 and August 31, 2020 were identified using
resultsA total of 5121 patients with IE with an average age of 55.7 years (SD:18.9) were included. Warfarin use was associated with lower risks of all-cause mortality with 12-week survival difference of 6.5% (95% CI, 2.6%-9.9%) and RR of 0.72 (95% CI, 0.57-0.88) and a greater benefit of achieving negative blood cultures with 12-week cumulative incidence difference of 11.4% (95% CI, 5.4%-16.5%) and RR of 1.13 (95% CI, 1.06-1.20) but similar risks of acute heart failure (RR, 1.07 [95% CI, 0.87-1.30]).
conclusionsPatients with IE initiating warfarin had significantly lower risk of mortality with potential benefits on achieving negative blood cultures, suggesting benefit in infection resolution but a similar risk of acute heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.